

Research Proposal Submission Form

**Discover Campaign:** Novel Technologies or Methods for Antibody-Drug Conjugation (ADC)

**Commissioning Organisation:** Client Requested Anonymity

**Deadline:** 20/02/2023

**Important notes on submitting this application form:**

This Submission Form is for novel research proposals related to “Novel Technologies or Methods for Antibody-Drug Conjugation (ADC)”. For existing/ongoing research projects and other opportunity types, an application form is not required. Once completed, please submit this form online using the link below, selecting “Research Project as the submission type:

1. Visit <https://discover.in-part.com>
2. Select the corresponding Discover campaign and upload this application document
3. Once uploaded you will be able to view the status of your submission and be notified with the date of an expected decision

If you have any questions regarding the completion or submission of your application, or any other aspect of the Discover process, please do not hesitate to reach out to [discover@in-part.co.uk](mailto:discover@in-part.co.uk). Additionally, answers to university FAQs can be found [here](https://in-part.com/blog/in-part-discover-faqs/).

Thank you for participating in this Discover campaign!

**Application form**

**Principal Investigator/Lead Researcher/Founder Information**

**Applicant Details\***

| Title |  |
| --- | --- |
| Forename(s) |  |
| Surname |  |
| Institution |  |
| Institution address |  |
| Institution postcode |  |
| Email address |  |
| Telephone number |  |

\* Please copy table for each co-applicant/team member as required

**Details of Opportunity**

**Opportunity Summary**

| Application Date |  |
| --- | --- |
| Submission title |  |

**Stage of Development (*where applicable*)**

| Target Identification | [ ] |
| --- | --- |
| Hit Finding | [ ] |
| Hit to Lead | [ ] |
| Lead Optimisation | [ ] |
| Preclinical Candidate, IND ready | [ ] |
| Clinical Phase I | [ ] |
| Clinical Phase II | [ ] |

**Applicable Diseases (*where applicable*)**

| **Please provide any information of applicability to disease** |
| --- |
|  |

**Please provide the information detailed in the table below:**

| A summary of your research proposal, including how it aligns with client interests. Include a description of key technologies and assays (*in vitro* and/or *in vivo*) available to support the project (maximum of 300 words). |
| --- |
|  |
| An outline of the proposal, including timeline, key milestones, and key methods and/or technologies to be used. |
|  |
| A summary of any background and/or ongoing research that supports the proposal including key data and any publications. |
|  |
| The key outcomes expected from this research proposal. |
|  |
| Any background IP that will be used in this research (where applicable). |
|  |

**Collaboration Sought**

| What resources would you require from our client in order to fulfill the full brief? |
| --- |
|  |

**Further Information**

| Is there any additional information you wish to share? |
| --- |
|  |

**IP and Legal Considerations (*where applicable*)**

| If applicable, have you disclosed your research to your technology transfer office? |
| --- |
|  |
| If yes, who is your Case Manager? Please include their email address. |
|  |
| Is there any IP filed for your opportunity? If so, please provide a patent reference. |
|  |
| Please list any research funding previously received in support of this research. |
|  |

**Essential Information and Guidance**

1. **Application process and timeline overview**

Submission

* All applicants should ensure information contained in the submission is non-confidential and approved by the relevant technology transfer office.
* Academic teams must complete and submit the application form associated with this campaign by 20/02/2023.
* All submissions should be provided to IN-PART using your university’s online dashboard or by emailing: [discover@in-part.co.uk](mailto:discover@in-part.co.uk)
* IN-PART will acknowledge receipt of your submission once received.

Review

IN-PART will provide our client with all applications, who will review all applications by 20/04/2023.

Successful applicants

Successful applicants, alongside a representative from their university’s Technology Transfer or Research Commercialisation team, will be informed by IN-PART, and introduced to the client team for next stage discussions.

Unsuccessful applicants

Feedback on unsuccessful applications will be provided by IN-PART shortly after 20/04/2023.

1. **Success criteria**

The client will judge each submission on a case by case basis. Please review the Discover campaign in detail to ensure your application addresses the research topic and fulfills the criteria for a successful application.

1. **Eligibility criteria**

Applicants must be associated with an academic research institution.

1. **Essential information on IP**

Prior to the commencement of the project, the institution will enter a project collaboration agreement with the Client. The project collaboration agreement will set the provisions on IP, exploitation of the results and publication.

Briefly, under the project collaboration agreement:

i) Inventions by each party alone: Attribute solely to the party.

ii) Joint inventions by the academia/spinout and the client researcher: Attribute to both parties.

iii) Academia/Spinout shall grant a non-exclusive, royalty-free license to the Client and its affiliates for internal research and/or non-commercial purposes.

1. **Publication and presentation of results**

Publication or presentation of results will be encouraged, however if this contains confidential information or potentially patentable subject matter, the publication or presentation will be delayed until steps are taken for the deletion or protection of such information or subject matter.